Comparison of Genomic and Transcriptomic Patterns Between the Circulating Tumor Cells and Metastatic Tumor Cells, and Their Specific Relevance to Circulating Tumor DNAs: Quest for Any Distinct or Complementary Roles of CTCs and ctDNAs to Understand the Metastasis in Advanced NSCLC

Samsung Medical Center1 site in 1 country20 target enrollmentJune 1, 2021

ConditionsNSCLC Stage IV NSCLC Stage IIIB

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: NSCLC Stage IV
Sponsor: Samsung Medical Center
Enrollment: 20
Locations: 1
Primary Endpoint: The gene expression and the cell population
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study aims to understand the metastasis in advanced NSCLC through comparing genomic and transcriptomic patterns between the circulating tumor cells and metastatic tumor cells by single cell sequencing analysis.

Registry

clinicaltrials.gov

Start Date

June 1, 2021

End Date

December 1, 2022

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Samsung Medical Center

Responsible Party

Principal Investigator

Jhingook Kim, MD

Professor

Samsung Medical Center

Eligibility Criteria

Inclusion Criteria

•All subjects need to sign the informed consent form
•All subjects have non-small cell lung cancer which suspected on chest CT or confirmed pathologically preoperatively
•Treatment naïve advanced lung cancer (including extensive stage IIIb and stage IV)
•Patients who were suitable to provide enough metastatic tumor tissue and blood (30ml) for the single cells sequencing

Exclusion Criteria

•Patients with previous history of lung cancer
•Have been undergone chemotherapy or radiotherapy due to non-small call lung cancer
•Have been diagnosed any type of cancer other than cancer of skin, thyroid, uterine cervix within 5 years before enrollment

Outcomes

Primary Outcomes

The gene expression and the cell population

Time Frame: 3 year

Methods for the single cell RNA sequencing and whole exome sequencing of the tumor cells With the tissue biopsied specimens, scRNAseq (by 10X Genomics platform) and whole exome seq will be carried out.